BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 26977595)

  • 1. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
    Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
    PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection.
    Jin Y; Liang ZY; Zhou WX; Zhou L
    J Invest Surg; 2018 Oct; 31(5):412-419. PubMed ID: 28758812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
    Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor.
    Zhuang PY; Zhang JB; Zhu XD; Zhang W; Wu WZ; Tan YS; Hou J; Tang ZY; Qin LX; Sun HC
    Cancer; 2008 Jun; 112(12):2740-8. PubMed ID: 18412155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CK19 can be used to predict the early recurrence and prognosis of HBV-related hepatocellular carcinoma patients with low AFP serum concentration after R0 radical hepatectomy].
    Wang ZS; Wu LQ; Yi X; Geng C; Li YJ; Yao RY; Hu WY; Han B
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):753-8. PubMed ID: 23291069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection.
    Lee CW; Kuo WL; Yu MC; Chen TC; Tsai CN; Lee WC; Chen MF
    World J Surg Oncol; 2013 Jun; 11(1):136. PubMed ID: 23758804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
    Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
    APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
    Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
    Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
    Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
    Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
    Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
    Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
    Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
    Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
    Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
    Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
    Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
    World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
    Yuan RH; Jeng YM; Hu RH; Lai PL; Lee PH; Cheng CC; Hsu HC
    J Gastrointest Surg; 2011 Feb; 15(2):321-9. PubMed ID: 21061181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy.
    Chen IP; Ariizumi S; Nakano M; Yamamoto M
    J Gastroenterol; 2014 Jan; 49(1):117-25. PubMed ID: 23532638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.
    Abdul-Al HM; Wang G; Makhlouf HR; Goodman ZD
    Int J Surg Pathol; 2010 Oct; 18(5):313-8. PubMed ID: 20444731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.